SCHEMBL4862870

SCHEMBL4862870

COC(=O)/C=C(/C)c1cc2c(Br)cccc2n1S(=O)(=O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
HTR6 P50406 3/20 0.42
HTR1A P08908 1/20 0.42
DRD2 P14416 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
HTR1F P30939 1/20 0.42
HTR7 P34969 1/20 0.42
DRD3 P35462 1/20 0.42
MTNR1B P49286 1/20 0.42
HDAC1 Q13547 6/20 0.39
HDAC2 Q92769 6/20 0.39
HDAC6 Q9UBN7 6/20 0.39
HDAC3 O15379 4/20 0.39
HDAC4 P56524 4/20 0.39
HDAC7 Q8WUI4 4/20 0.39
HDAC10 Q969S8 4/20 0.39
HDAC11 Q96DB2 4/20 0.39
HDAC8 Q9BY41 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14203293 1.00 MEN1 (0.43) MEN1KMT2AHTR6HTR1ADRD2
SCHEMBL4862879 1.00 MEN1 (0.43) MEN1KMT2AHTR6HTR1ADRD2
SCHEMBL16796477 0.84 MEN1 (0.51) MEN1KMT2AHTR6HTR1ADRD2
SCHEMBL4852200 0.83 HTR6 (0.49) MEN1KMT2AHTR6HTR1ADRD2
SCHEMBL16812952 0.80 HTR6 (0.48) HTR6HTR1ADRD2HTR1DHTR1B
SCHEMBL16796488 0.78 SRC (0.47) HTR6HTR1ADRD2HTR1DHTR1B
SCHEMBL10004275 0.77 NOD2 (0.60) MEN1KMT2AHTR6HTR1ADRD2
SCHEMBL30889670 0.76 NOD1 (0.53) MEN1KMT2AHTR6LMNAPSEN1
SCHEMBL597369 0.74 HTR6 (0.46) HTR6LMNASMN1; SMN2PSEN1PSEN2
SCHEMBL30644289 0.74 HTR6 (0.46) HTR6LMNASMN1; SMN2PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090860-A1 Retinoid x receptor modulators GARDINIER KEVIN M 2008-04-17 US disclosed
US-7348359-B2 Retinoid X receptor modulators ELI LILLY AND COMPANY (US) 2008-03-25 US disclosed
EP-1373240-B1 RETINOID X RECEPTOR MODULATORS LILLY CO ELI (US) 2005-06-15 EP disclosed
US-20040167160-A1 Retinoid x receptor modulators LIGAND PHARMACEUTICALS INCORPORATED 2004-08-26 US disclosed
EP-1373240-A2 RETINOID X RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-01-02 EP disclosed
WO-2002071827-A2 RETINOID X RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167160-A1 Retinoid x receptor modulators RXRA, RXRG, RXRB MEN1 4117/4885KMT2A 4050/4885HTR6 1111/4885
US-20080090860-A1 Retinoid x receptor modulators RXRA, RXRG, RXRB MEN1 4261/4885KMT2A 4112/4885HTR6 1102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.